position." Perceptive's most recent buy is Amicus Therapeutics (NASDAQ: FOLD ) . The fund bought 8,339,444 shares on May ..... million additional shares were added on the day that Amicus announced trial updates and analysis Complete
Shares of Amicus Therapeutics ( FOLD +22.8% ) continue upward on a 7x surge in volume in early trading. Yesterday, prices peaked at $4.06 before easing a bit
** Says on track to report data from a late-stage trial of its genetic disorder drug in the third quarter of this year
Amicus Therapeutics ( FOLD ) says that top-line data and statistical analysis from the clinical trail ( Study 012 ) evaluating its oral small molecule pharmacological
Neuroscientist Investor : Name: Amicus Therapeutics ( FOLD ) Current share price: $2 ..... Summary of investment thesis: Amicus Therapeutics is a rare disease drug developer ..... partnership rights. However, FOLD has since updated clinical
historical norms. On the flip side, and in a case like Amicus Therapeutics ( FOLD ), once investors have largely written off a company ..... interest and confidence. To be very clear, I believe Amicus still has a difficult road ahead of it. The data
(Reuters) - Amicus Therapeutics Inc lost nearly half of its market value after the company said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage...
(Reuters) - Amicus Therapeutics said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage study, sending its shares down 50 percent in extended...
We are no longer providing equity research on Amicus Therapeutics FOLD . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
Shire's collaboration with Amicus also bodes poorly for Amigal ..... only worsen the problem. Amicus is more dependent than ever ..... future drug development. Amicus aims to use its innovative ..... partner to market them abroad. Amicus Therapeutics aims to stand on the shoulders